Key Highlights

  • AstraZeneca PLC (LSE:AZN) reported third-quarter Revenue of $16.21 billion, up 7%, and core EPS of $2.79, up 17%, on 30 October 2026.
  • The FTSE 100 drugmaker reconfirmed 2026 guidance of mid-to-high single-digit revenue growth and low double-digit core EPS growth.
  • Management announced a restructuring programme targeting $1.5 billion in annual savings by 2029.
  • CEO Pascal Soriot said 2027 trial readouts could represent more than $20 billion of peak annual revenue.
  • The FTSE 100 closed up 1.02% at 10,782.87 on 9 November 2026.

Why AstraZeneca (LSE:AZN) Is in Focus Today

AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 by many measures, is in focus on Monday 9 November 2026 as investors digest strong third-quarter numbers and an ambitious pipeline outlook. The FTSE 100 closed up 1.02% at 10,782.87, and defensive healthcare names attracted interest as markets rebounded from last week's technology-led sell-off.

The shares had jumped about 5% in pre-market trading on 30 October after the results, taking them toward their 200-day average for the first time since July from a level near 13,050p.

Third-Quarter Results

Total revenue rose 7% at constant currency to $16.21 billion, beating estimates of about $16 billion. Core Earnings Per Share increased 17% to $2.79, or 19% at constant exchange rates, well ahead of consensus around $2.59. For the nine months, total revenue was $46.88 billion, up 7%, and core operating profit was $16.4 billion, up 14%.

Reported earnings per share rose 23% in the quarter to $2.02. Alliance revenue grew 36%, reflecting the contribution of partnerships on drugs such as Enhertu.

Oncology Leads Growth

Oncology, now 47% of revenue at $21.9 billion for the nine months, grew 16%. Respiratory and Immunology rose 10% and Rare Disease grew 11%. These gains offset headwinds in cardiovascular, renal and metabolism, which fell 14% because of loss of exclusivity on Farxiga and Brilinta, and volume-based procurement in China.

Management highlighted 47 approvals in major regions since the last full-year results, including first approvals for four new medicines, and 12 positive Phase III readouts with combined peak revenue potential well above ten billion dollars.

Savings Programme and 2027 Readouts

AstraZeneca announced a restructuring programme aimed at $1.5 billion of annual savings by 2029, giving shareholders a Margin tailwind alongside growth. Soriot said a rich series of readouts in 2027 has potential peak annual revenue of more than twenty billion dollars, from a pipeline of more than 180 projects including 20 new molecular entities in late-stage development.

The company is on track for its 2030 ambition and says 14 new molecular entities have been delivered against a target of 20 by 2030.

Guidance and Deals

Full-year 2026 guidance was reconfirmed at constant exchange rates: revenue growth in the mid-to-high single digits and core EPS growth in the low double digits, with a core tax rate of 18% to 22%. Currency is expected to add a low single-digit percentage to revenue if rates stay at September levels.

In October, AstraZeneca completed a $2 billion Equity Investment in Summit Therapeutics and announced a drug discovery agreement with insitro, reflecting an active approach to external innovation.

Risks to Consider

Trial readouts carry binary risk, as seen when SERENA-4 missed its primary endpoint and volrustomig was discontinued for futility. Pricing pressure in the United States and China, policy changes affecting drug costs, and Patent expiries remain key concerns.

The shares trade at a premium multiple to many peers, so delays or setbacks in the late-stage pipeline could affect sentiment.

Product Portfolio and Growth Engines

AstraZeneca's growth relies on a handful of large franchises. Enhertu, developed with a partner, is expanding into earlier lines of breast cancer and other tumour types, while Imfinzi, Tagrisso and Lynparza provide established oncology revenue. In respiratory, Tezspire and Breztri continue to broaden their indications, and Rare Disease drugs such as Ultomiris add high-margin growth.

The company has also invested in new technologies, including cell therapy, radioconjugates and artificial intelligence-enabled drug discovery, which management says are scaling rapidly.

Dividend and Capital Allocation

The group pays a progressive Dividend and has a significant capital programme, including investment in United States Manufacturing and research. Business development remains active, and the $2 billion Summit Therapeutics investment is an example of securing access to emerging assets.

Investors will look to the full-year results for details of cash generation after restructuring costs and how the savings programme interacts with research spending.

What Investors Are Watching Next

Investors will track upcoming data presentations at medical conferences, regulatory decisions in the US, EU, Japan and China, and updates on the savings programme. Further business development, including acquisitions, may also feature.

The full-year results in February will give updated guidance for 2027, and any detail on how the cost programme and pipeline will translate into margin and earnings growth will be closely scrutinised.